Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly

Red Cell Survival in Healthy Volunteers

Red cell survival in INTERCEPT treated red cells

Hoxworth Blood Center

Recovery and Lifespan of Red Blood Cells From Pathogen-reduced, Stored Blood Units

Measurement of the Recovery and Lifespan of Red Blood Cells From Pathogen-Reduced, Stored Blood Units Using Cellular Biotinylation

Jose Cancelas

Professor, Research Division Director, Hoxworth Blood Center

University of Cincinnati

Cerus Corporation

Biomedical Advanced Research and Development Authority

32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).

Hemolytic Disorders

Gallstones

Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.
Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose.

Ursodeoxycholic Acid

Shaare Zedek Medical Center

The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders

including non-specific abdominal discomfort, rash or nausea.

reduced gamma-glutamyl-transpeptidase (GGT) and alkaline phosphatase (ALP).

Liver Fibrosis Progression in Chronic Liver Disease

Hôpital Pitié-Salpêtrière

LIVER FIBROSIS PREVALENCE IN FRANCE

At least one year follow up for fibrosis progression rate.

For Mortality and Morbidity one assessment at five years and one assessment at 10 years.

DRCD12

Professor Thierry POYNARD

Assistance Publique - Hôpitaux de Paris

Fenretinide (4-HPR) plus Intravenous Safingol

Solid Tumor

A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.
Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects.

University of Texas Southwestern

Joe Arrington Cancer Center/Covenant Children's Hospital

University Medical Center

Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies

The primary outcome mesure of this study is to determine the maximum tolerated dose (MTD) of an intravenous (emulsion) safingol when administered as a continuous intravenous (c.i.v.) infusion for two days, once every 3 weeks, in combination with fenretinide (4-HPR) intravenous emulsion administered as a continuous intravenous infusion for five days, once every 3 weeks.

hemolysis/triglyceride

Recovery and Lifespan of Red Blood Cells From Pathogen-reduced, Stored Blood Units

The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders

LIVER FIBROSIS PREVALENCE IN FRANCE

Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

Najkompletnejšia databáza liečivých bylín podporovaná vedou